FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial. PMID 41774886 · J Clin Oncol · 2026-Apr-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update. PMID 41747202 · J Clin Oncol · 2026-Apr-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes, Moderators, and Predictors in Online Mindfulness-Based Cognitive Therapy for People With Cancer: Secondary Analysis of a Randomized Controlled Trial. PMID 41996463 · J Med Internet Res · 2026-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Probiotics on the Clinical Outcome and Inflammatory Response in Gastric Cancer Surgery: A Double Blinded Randomized Control Trial. PMID 41996041 · J Gastrointest Cancer · 2026-Apr-17 Study is a randomized trial in gastric cancer but is excluded because it does not involve a drug-containing intervention (probiotics are not a drug) and its primary endpoints are postoperative recovery metrics, not oncology time-to-event efficacy outcomes like OS or PFS. Phase is not stated. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol. PMID 41992146 · BMC Cancer · 2026-Apr-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy. PMID 42003280 · Cancer · 2026-Apr-15 The study is a Phase 2 randomized trial in oncology patients with a drug intervention, but it does not meet the definitive phase requirement (Phase III/IIIb or Phase II/III) and does not report a time-to-event efficacy endpoint, which are required for inclusion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial. PMID 41986386 · Nat Commun · 2026-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Protocol of a randomised controlled trial: comparing the safety and efficacy of two methadone conversion strategies in Chinese patients with cancer pain receiving high-dose opioids. PMID 41985948 · BMJ Open · 2026-Apr-15 This is a clinical trial protocol (not a results report) for a randomized trial in cancer pain. While it involves oncology patients, human subjects, randomization, and a drug intervention, it does not present primary or secondary results. The primary efficacy endpoint is time to stable analgesia (not a time-to-event survival endpoint like OS/PFS). No Kaplan-Meier or HR data are reported. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical Trial. PMID 41983724 · Ann Surg · 2026-Apr-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors. PMID 41591997 · Clin Cancer Res · 2026-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol. PMID 41981510 · BMC Cancer · 2026-Apr-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 42073552 · Cancers (Basel) · 2026-Apr-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of prevention of postoperative pulmonary complications with penehyclidine inhalation on long-term outcomes in high-risk patients: follow-up of a randomized trial. PMID 41973092 · J Anesth · 2026-Apr-13 The study is excluded because the drug intervention (penehyclidine) is not an oncology therapeutic agent; it is a perioperative supportive care measure aimed at preventing pulmonary complications, not treating the underlying malignancy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical value of intraoperative frozen section examination-assisted strategy in prostate biopsy: a comparative study of diagnostic efficiency and clinical practicality. PMID 41968340 · BMC Cancer · 2026-Apr-13 Study is a randomized, prospective, human oncology (prostate cancer) trial with original results. However, it is not a Phase III/IIIb or Phase II/III trial (phase not specified but appears to be a diagnostic study, not a definitive drug trial). It lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. It evaluates a diagnostic procedure (biopsy strategy), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Effect of electroacupuncture on intestinal function after laparoscopic colorectal cancer surgery]. PMID 41987441 · Zhongguo Zhen Jiu · 2026-Apr-12 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| [Effects of electroacupuncture on gastrointestinal dysfunction and serum metabolites in postoperative patients with gastric cancer]. PMID 41987440 · Zhongguo Zhen Jiu · 2026-Apr-12 The study is an oncology RCT in humans but is ineligible because the intervention is non-drug (electroacupuncture) and it lacks a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Expiratory Muscle Strength Training in Head and Neck Cancer Survivors With Radiation-Associated Dysphagia: Results of a Pilot Prospective Trial. PMID 41964362 · Head Neck · 2026-Apr-11 The record describes a single-arm pilot study of a non-drug intervention (expiratory muscle strength training) in head and neck cancer survivors. It lacks randomization, a drug intervention, and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors. PMID 41912436 · Oncologist · 2026-Apr-10 The record is from a randomized Phase III oncology trial with a drug intervention, but the reported analysis focuses on cardiac biomarkers and safety, not a primary or key secondary time-to-event efficacy endpoint like OS or PFS. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. PMID 41734362 · J Clin Oncol · 2026-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Bayesian adaptive randomization in the I-SPY2 sequential multiple assignment randomized trial. PMID 42053379 · Biometrics · 2026-Apr-09 The record describes the I-SPY2 SMART as a Phase 2 platform trial, not Phase III/IIIb. It is a methodology paper presenting a Bayesian adaptive randomization scheme, not a primary report of trial results with a time-to-event efficacy endpoint. The primary endpoint is pathological complete response (pCR), which is not a time-to-event outcome (OS, PFS, DFS, etc.). The intervention involves novel agents, but the paper focuses on the trial design and randomization algorithm, not on reporting specific drug intervention efficacy results. Therefore, it fails multiple key eligibility criteria: it is not a Phase III trial, lacks a time-to-event endpoint, is not a drug intervention efficacy result report, and is not an original formal trial result. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study. PMID 41956546 · J Immunother Cancer · 2026-Apr-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Survival after breast-conserving surgery and radiotherapy versus mastectomy: propensity score analyses within a randomized anaesthesiology trial. PMID 41954954 · Br J Surg · 2026-Apr-09 The record is a secondary analysis of survival outcomes from a randomized trial that compared anesthesia types, not a drug intervention. While the cohort is from a randomized trial and the endpoints are time-to-event efficacy outcomes (OS, BCSS), there is no drug-containing intervention, and the trial is not a Phase III/IIIb or Phase II/III oncology drug trial. Therefore, it does not meet the core eligibility criterion of a drug intervention in an oncology Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches. PMID 41642077 · Jpn J Clin Oncol · 2026-Apr-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901). PMID 41956861 · Eur Urol · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Palbociclib in the Treatment of HR+/ HER2- Advanced or Metastatic Breast Cancer in Australia: A Real-World Retrospective Analysis. PMID 41952090 · Asia Pac J Clin Oncol · 2026-Apr-08 The study is a non-interventional, retrospective cohort analysis. It is not a randomized controlled trial, and there is no evidence it is a Phase III or definitive trial, as it is a real-world observational study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial. PMID 41951687 · NPJ Breast Cancer · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial. PMID 41951647 · Nat Commun · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Initial testing of a mobile app behavioral pain coping intervention for patients with cancer: Results of a pilot randomized controlled trial. PMID 41950509 · J Psychosoc Oncol · 2026-Apr-08 This is a pilot randomized trial in cancer patients, but it does not meet core eligibility criteria. It lacks a drug-containing intervention (interventions are behavioral pain coping via app or video). It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as the focus is on feasibility, acceptability, and pain outcomes. It is not a Phase III/IIIb or definitive Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. PMID 41712219 · JAMA · 2026-Apr-07 The study is an oncology Phase 3 randomized trial comparing two radiation therapy regimens for brain metastases. It is eligible for oncology, human, randomized, and phase criteria. However, it is excluded because the intervention is non-drug (radiation therapy only) and the primary endpoint is a patient-reported symptom score change, not a time-to-event efficacy endpoint like OS, PFS, or DFS. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Progress in management of advanced clear-cell renal cell carcinoma. PMID 41941086 · Clin Transl Oncol · 2026-Apr-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Intratympanic Dexamethasone Efficacy in Preventing Cisplatin-induced Tinnitus: A Randomized Controlled Phase IIIB Clinical Trial. PMID 41940636 · Ear Hear · 2026-Apr-06 The study is a randomized, phase IIIB trial with a drug intervention in an oncology context, but the primary endpoint is the prevention of a toxicity (tinnitus), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). Therefore, it does not meet the key criterion for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Development and implementation of personalized postoperative care plans for gynecological oncology patients under the precision medicine paradigm: strategies to enhance patient participation and self-management capacity. PMID 41937146 · World J Surg Oncol · 2026-Apr-06 The study is a randomized oncology trial reporting time-to-event efficacy outcomes (DFS, EFS) with Kaplan-Meier analysis and HR. However, it is ineligible because the intervention is a non-drug-only behavioral/digital care pathway, and the trial phase is not explicitly identified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial. PMID 41937137 · BMC Med · 2026-Apr-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparative long-term sedation efficacy of remimazolam vs propofol in malignant patients with mechanical ventilation: an exploratory non-inferiority randomized study. PMID 41935116 · Sci Rep · 2026-Apr-04 The record does not meet the eligibility criteria. While it is an oncology, human, randomized, drug-intervention trial with original results, the required Phase III/IIIb or Phase II/III evidence is not established from the provided metadata. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, etc.) suitable for Kaplan-Meier digitization. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Validating National Registry Data for Randomised Trials: Comparison of registry-derived cardiovascular events with and without adjudication in the BETAMI-DANBLOCK trial. PMID 41934630 · Eur Heart J Qual Care Clin Outcomes · 2026-Apr-04 The trial is a cardiovascular registry-based randomized trial for beta-blocker therapy in myocardial infarction patients, not an oncology study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial. PMID 41976378 · Cancers (Basel) · 2026-Apr-03 The trial is a Phase IIb randomized study (not Phase III/IIIb or Phase II/III) and its primary endpoint is an incidence rate (EAIR) of a safety/toxicity outcome (hyperglycemia), not a primary/key time-to-event efficacy endpoint like OS, PFS, etc. While efficacy is mentioned as a secondary endpoint, it is not defined as a time-to-event outcome in the abstract, nor are KM curves or HRs reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The efficacy of combined bandage contact lens and nasal margin suture fixation in pterygium patients and its impact on inflammatory cytokines. PMID 41933093 · Sci Rep · 2026-Apr-03 The study is not an oncology trial; it investigates pterygium (a benign ocular surface condition) using surgical and suture techniques, not a drug intervention for malignant neoplasms. It lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vaginal natural orifice transluminal endoscopic surgery versus laparoscopy for ovarian cystectomy: a prospective, open-label, randomized, non-inferiority pilot trial. PMID 41931151 · Arch Gynecol Obstet · 2026-Apr-03 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma. PMID 41959823 · medRxiv · 2026-Apr-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). PMID 41934038 · Eur Urol · 2026-Apr-02 The record is a letter to the editor responding to a previously published trial report. The title explicitly states 'Re:', and no abstract is provided to verify the necessary inclusion criteria. Therefore, it is not an original formal result report of a randomized trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial. PMID 41927289 · BMJ Open · 2026-Apr-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Anesthetic approaches and 2-year recurrence rates in non-muscle invasive bladder cancer: a randomized clinical trial. PMID 39740955 · Reg Anesth Pain Med · 2026-Apr-02 The study is an oncology RCT with time-to-event outcomes, but the intervention compares anesthesia techniques (spinal vs. general), not a drug-containing regimen. It lacks explicit Phase III/IIIb or Phase II/III evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis. PMID 41983220 · Hepatobiliary Surg Nutr · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab). PMID 41960901 · Cancer Res Commun · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy: A Secondary Analysis of a Cluster Randomized Clinical Trial. PMID 41941188 · JAMA Netw Open · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of dexmedetomidine on recovery of postoperative gastrointestinal function in patients with adhesive bowel obstruction: a single-center randomized clinical trial. PMID 41917824 · BMC Anesthesiol · 2026-Apr-01 The study is not in oncology (malignant neoplasm). It investigates postoperative GI function recovery in adhesive bowel obstruction, which is a non-malignant, non-oncologic condition. Therefore, it fails the fundamental oncology criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial. PMID 41746629 · JAMA Oncol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial. PMID 41677407 · Crit Care Med · 2026-Apr-01 The study is a randomized, placebo-controlled trial in septic shock, not in oncology. The primary endpoint is an inflammatory biomarker (Tumor Necrosis Factor-alpha), and while 28-day mortality is reported, it is a secondary endpoint without KM plot or HR analysis provided in the abstract. Therefore, it does not meet the core oncology or time-to-event endpoint criteria for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cognitive-Behavioral Sleep and Nutritional Intervention Enhances Recovery and Survival in Rectal Cancer Patients Undergoing Abdominoperineal Resection: A Randomized Controlled Trial. PMID 41642757 · Biopsychosoc Sci Med · 2026-Apr-01 Eligible on most criteria (oncology, human, randomized, time-to-event), but excluded because the intervention is non-drug-only (behavioral and nutritional) and no drug-containing intervention is present. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Investigator-led clinical trial of boron neutron capture therapy system for recurrent high-grade meningiomas after radiation therapy: Randomized phase II study. PMID 41560342 · Neuro Oncol · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |